BOB体育

Skip to main content
(352) 273-8740

Ali Ataya, MD : Research

Critical Care Medicine Specialist, Pulmonologist (Lung Specialist)

Photo of Ali Ataya
(352) 273-8740 MyUFHealth

Research at a glance

Top areas of exploration

  • Dyspnea , 14 publications
  • Hypertension, Pulmonary , 6 publications
  • Pulmonary Alveolar Proteinosis , 5 publications
  • Lung , 5 publications

Research activity

116 publications

405 citations

Why is this important?

Active clinical trials

IMPALA-2

160 subjects with autoimmune pulmonary alveolar proteinosis (aPAP) will be randomized to receive once daily treatment with inhaled molgramostim or placebo for 48 weeks. Subjects completing the 48 week placebo-controlled period will receive鈥�

Investigator
Ali Ataya
Status
Accepting Candidates
Ages
18 Years - N/A
Sexes
All
ROR-PH-303 (APD811-303)

Study ROR-PH-303, ADVANCE EXTENSION, is an open-label extension (OLE) study for participants with WHO Group 1 PAH who have participated in another Phase 2 or Phase 3 study of ralinepag.

Investigator
Ali Ataya
Status
Accepting Candidates
Ages
18 Years - N/A
Sexes
All
United therapeutics 301

Study ROR-PH-301, ADVANCE OUTCOMES, is designed to assess the efficacy and safety of ralinepag when added to pulmonary arterial hypertension (PAH) standard of care or PAH-specific background therapy in subjects with World Health Organization (WHO)鈥�

Investigator
Ali Ataya
Status
Accepting Candidates
Ages
18 Years - N/A
Sexes
All

My publications

116 publications

2024

Practical management of oral treprostinil in patients with pulmonary arterial hypertension: Lessons from ADAPT, EXPEDITE, and expert consensus

Respiratory Medicine

2024

Progressive Dyspnea on Exertion in an 82-Year-Old.

JAMA

鈥�

2024

Progressive Exertional Dyspnea in a Patient with Epistaxis, Telangiectasias, and Arteriovenous Malformations.

Annals of the American Thoracic Society

鈥�

2024

Pulmonary hypertension during high鈥恉ose GM鈥怌SF therapy of autoimmune pulmonary alveolar proteinosis

Pulmonary Circulation

鈥�

2024

Unsupervised Exercise in Interstitial Lung Disease: A Delphi Study to Develop a Consensus Preparticipation Screening Tool for Lymphangioleiomyomatosis.

Chest

鈥�